Business Wire

PA-STRATUS-MATERIALS

25.6.2024 15:02:03 CEST | Business Wire | Press release

Share
Stratus Materials Announces Achievement of Key Performance Milestone for its LXMOTM Li-ion Battery Cathode Active Material

Stratus Materials Inc., a company focused on the development and commercialization of advanced cathode active materials (CAMs) for lithium-ion batteries, today announced that its first-generation LXMO CAM material has achieved a significant milestone associated with cycling durability in electric vehicle applications.

This month, LXMO-containing pouch cells surpassed 1,000 full depth-of-discharge cycles while maintaining greater than 80% of their initial capacity, a common goal across the EV battery industry. The 3rd party-built cells used standard cell and electrode designs, employing a natural graphite anode and an electrolyte of standard industry components, to work in conjunction with the Stratus cathode material. The cells in the test group maintained 82-86% of their initial capacity and are projected to exceed 1,200 cycles before reaching 80% of their initial capacities. At the same 1,000-cycle point, the average discharge voltage of the cells maintained approximately 97%, dropping only 0.1 V from their initial values. The excellent capacity and voltage stability of the cells surpass the energy retention of many commercial materials in use today.

Jay Whitacre, CEO & CTO of Stratus Materials (and Professor at Carnegie Mellon University), said: “These cells have been cycling for the last 10 months and clearly demonstrate that our proprietary materials are able to meet EV industry durability needs. To our knowledge this is the first time such minimal loss in cell voltage has been documented for this class of materials. The Stratus team looks forward to building upon these strong technical results as we improve, commercialize, and scale production in the coming quarters.”

Stratus products are in the lithium-rich, manganese-rich (LMR) category of cathode active materials. LMR cathodes have garnered significant interest in the Li-ion battery and EV industries due to several highly promising attributes including high energy density, low cost, and high safety. However, despite being in development around the world for over two decades, LMRs have not yet been commercially deployed because of several persistent technical challenges – primarily the voltage and capacity instability issues that Stratus Materials has largely overcome, as demonstrated by its latest results. With its continued technological progress, Stratus Materials is focused on enabling the first fully functional, LMR-class CAMs that are suitable for full-scale, commercial use.

Scott Pearson, President & CCO, added: “We are thrilled to show that our first-generation LXMO material can exceed this EV cell durability target while also delivering a set of highly compelling advantages versus incumbent CAMs. We expect that this proof point will be one of many that we will be offering to our industry partners and customers.”

Stratus is currently producing materials on its existing pre-pilot production line in Pittsburgh, Pennsylvania and has ongoing sampling efforts underway with many of the leading companies in the EV and EV battery industries. As previously announced, the company will be increasing its production capabilities from pre-pilot to pilot scale later in 2024.

ABOUT STRATUS MATERIALS

Stratus Materials (www.stratusmaterials.com) is a U.S. based company focused on the development and commercialization of next-generation cathode active materials (CAMs) for lithium-ion batteries. Our mission is to disrupt the CAM supply chain by offering materials with a game-changing combination of performance, safety, and cost. Stratus is primarily focusing its cobalt-free LXMOTM cathode products on light- and medium-duty electric vehicles and other applications with similar requirements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625022288/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye